Screener
Stoke Therapeutics, Inc. STOK Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from issuance of common stock upon exercise of stock options | 3,205 | 1,004 |
| Proceeds from issuance of common stock in controlled equity offering sales agreements | 80,657 | — |
| Net cash provided by financing activities | 84,327 | 1,374 |
| Net increase in cash, cash equivalents and restricted cash | 74,439 | 146,833 |
| Cash, cash equivalents and restricted cash—beginning of period | 84,941 | 128,780 |
| Cash, cash equivalents and restricted cash—end of period | $159,380 | $275,613 |
| Supplemental Disclosure of Non-Cash Investing and Financing Activities: | ||
| Property and equipment included in accrued expense and accounts payable | $334 | $27 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s net change in cash?
- Stoke Therapeutics, Inc. (STOK) reported net change in cash of $74.44M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s net change in cash changed year-over-year?
- Stoke Therapeutics, Inc.'s net change in cash decreased by 49.3% year-over-year, from $146.83M to $74.44M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s net change in cash?
- Over 3 years (2021 to 2025), Stoke Therapeutics, Inc.'s net change in cash has grown at a -32.0% compound annual growth rate (CAGR), from -$142.05M to -$44.66M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Stoke Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude